Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 3, 2003, Pages 193-201

  Mirsalis, Jon C ^a   Schindler Horvat, Janice ^a   Hill, James R ^a   Green, Carol E ^a   Mitoma, Chozo ^a   Tomaszewski, Joseph E ^b   Tyson, Charles A ^a   Donohue, Susan J ^b  

^a SRI INTERNATIONAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bone marrow toxicity; Gastrointestinal toxicity; Quinocarmycin analog DX 52 1; Renal toxicity; Species differences; Streptomyces melunovinaceus

Indexed keywords

ANTINEOPLASTIC AGENT; DX 521; QUINOCARMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; BODY SURFACE; BODY WEIGHT; BOLUS INJECTION; BONE MARROW TOXICITY; CELL DEATH; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DOG; DRUG EFFECT; DRUG INFUSION; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HEMATOCRIT; HEMATOLOGY; HISTOPATHOLOGY; HYPOTHERMIA; KIDNEY TUBULE NECROSIS; LIVER TOXICITY; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RETICULOCYTE; SEPTICEMIA; SHOCK; STREPTOMYCES; STREPTOMYCES MELANOVINACEUS; TISSUE NECROSIS; TOXEMIA; TOXICITY TESTING; UREA BLOOD LEVEL; VOMITING;

EID: 0037365090     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0553-0     Document Type: Article

References (21)

1. Bigelow J, Chrin L, Horton P, Mathews L, McCormack J (1994) Analytical and pharmacokinetic studies of a quinocarmycin derivative. Proc Am Assoc Cancer Res 35:427
2. Bregman CL, Comereski CR, Buroker RA, Hirth RS, Madissoo H, Hottendorf GH (1987) Single-dose and multiple-dose intravenous toxicity studies of BMY-25282 in rats. Fundam Appl Toxicol 9:90
3. Bunnell CA, Supko JG, Eder JP Jr, Clark JW, Lynch TJ, Kufe DW, Shulman LN (2001) Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. Cancer Chemother Pharmacol 48:347
4. Dykes DJ, Abbott BJ, Mayo JG, Harrison SD Jr, Laster WR Jr, Simpson-Herren L, Griswold DP Jr (1992) Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. In: Huber H, Queiber W (eds) Contributions to oncology, vol 42. Karger, Basel, p 1
5. Fiebig HH, Berger DP, Dengler WA, Drees M, Mayo J, Malspeis L, Grever M (1994) Cyanocyclin A and the quinocarmycin analog NSC 607097 demonstrate selectivity against melanoma xenografts in vitro and in vivo. Proc Am Assoc Cancer Res 35:468
6. Foley HT, Shnider BI, Gold GL, Matias PI, Colsky J, Miller SP (1967) Phase I studies of porfiromycin (NSC-56410). Cancer Chemother Rep 51:283
7. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 50:219
8. Fujimoto K, Oka T, Morimoto M (1987) Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152). Cancer Res 47:1516
9. Fuse E, Nishie H, Kobayashi H, Ikeda S, Saito H, Covey J, Kobayashi S (1997) Disposition of DX-52-1, a novel anticancer agent, after intravenous administration to mice and dogs. Eur J Drug Metab Pharmacokinet 22:53
10. Grage TB, Weiss AJ, Wilson W, Reynolds V (1975) Phase I studies of porfiromycin (NSC-56410) in solid tumors. J Surg Oncol 7:415
11. Inaba S, Shimoyama M (1988) Antitumor activity of quinocarmycin (KW2152) against various cultured leukemia and lymphoma cell lines in vitro. Cancer Res 48:6029
12. Inoue S, Kubota T, Ohishi T, Kuzuoka M, Oka S, Shimoyama Y, Kikuyama S, Ishibiki K, Abe O (1988) Antitumor activity of quinocarmycin citrate (KW-2152) against human tumor xenografts serially transplanted into nude mice. Keio J Med 37:366
13. Izbicki R, Al-Sarraf M, Reed ML, Vaughn CB, Vaitkevicius VK (1972) Further clinical trials with porfiromycin (NSC-56410) (large intermittent doses). Cancer Chemother Rep 56:615
14. Jett JR, Saijo N, Hong W-S, Sasaki Y, Takahashi H, Nakano H, Nakagawa K, Sakurai M, Suemasu K, Tesada M (1987) The colony inhibition of a new chemotherapeutic agent (KW2152) against human lung cancer cell lines. Invest New Drugs 5:155
15. Nosoh Y, Nishiyama M, Niimi K, Hirabayashi N, Toge T, Niimoto M, Hattori T (1987) Antitumor activities of KW-2152, a new isoquinone agent, against human tumor xenografts transplanted into nude mice. Jpn J Surg 17:146
16. Plowman J, Dykes DJ, Narayanan VL, Abbott BJ, Saito H, Hirata T, Grever MR (1995) Efficacy of the quinocarmycins KW2152 and DX-52-1 against human melanoma lines growing in culture and in mice. Cancer Res 55:862
17. Saito H, Kobayashi S, Uosaki Y, Sato A, Fujimoto K, Miyoshi K, Ashizawa T, Morimoto M, Hirata T (1990) Synthesis and biological evaluation of quinocarcin derivatives. Chem Pharm Bull 38:1278
18. Saito H, Hirata T, Kasai M, Fujimoto K, Ashizawa T, Morimoto M, Sato A (1991) Synthesis and biological evaluation of quinocarcin derivatives: thioalkyl-substituted quinones and hydroquinones. J Med Chem 34:1959
19. Tomaszewski JE, Smith AC (1997) Safety testing of antitumor agents. In: Williams PD, Hottendorf GH (eds) Comprehensive toxicology, toxicity testing and evaluation, vol 2. Elsevier Science, Oxford, p 299
20. Tomaszewski JE, Smith AC, Covey JM, Donohue SJ, Rhie JK, Schweikart KM (2002) Relevance of preclinical pharmacology and toxicology to Phase I trial extrapolation techniques. Relevance of animal toxicology. In: Baguley BC, Kerr DS (eds) Anticancer drug development. Academic Press, San Diego, CA, p 301
21. Tomita F, Takahashi K, Shimizu K (1983) DC-52, a novel antitumor antibiotic. 1. Taxonomy, fermentation and biological activity. J Antibiot (Tokyo) 36:463